John M Dye

List of Publications by Year
in descending order

111 papers	9,950 citations	44069 48 h-index	42399 92 g-index
125 all docs	125 docs citations	125 times ranked	13552 citing authors

#	Article	IF	Citations
1	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124.	12.4	143
2	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naÃ¯ve and Experienced Individuals. Viruses, 2022, 14, 370.	3.3	5
3	Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Science Translational Medicine, 2022, 14, eabl5399.	12.4	16
4	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
5	A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): <i>in silico</i> and <i>in vitro</i> investigations. RSC Medicinal Chemistry, 2021, 12, 1757-1764.	3.9	18
6	Toll-like receptor 4 mediates blood-brain barrier permeability and disease in C3H mice during Venezuelan equine encephalitis virus infection. Virulence, 2021, 12, 430-443.	4.4	10
7	Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods, 2021, 195, 57-71.	3.8	29
8	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	12.6	285
9	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	3.4	6
10	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science, 2021, 372, 1108-1112.	12.6	210
11	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021, 184, 3486-3501.e21.	28.9	39
12	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. International Journal of Biological Macromolecules, 2021, 183, 203-212.	7.5	28
13	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. Journal of Infectious Diseases, 2021, , .	4.0	3
14	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
15	Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorganic and Medicinal Chemistry, 2021, 47, 116393.	3.0	15
16	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. MBio, 2021, 12, e0247321.	4.1	35
17	Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. Frontiers in Immunology, 2021, 12, 729851.	4.8	5
18	On-Demand Patient-Specific Phenotype-to-Genotype Ebola Virus Characterization. Viruses, 2021, 13, 2010.	3.3	1

#	Article	IF	Citations
19	Neutralizing Antibodies against Crimeanâ€“Congo Hemorrhagic Fever Virus Derived from a Human Survivor. Proceedings (mdpi), 2020, 50, .	0.2	0
20	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science, 2020, 369, 1261-1265.	12.6	520
21	BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals. Antiviral Research, 2020, 184, 104966.	4.1	10
22	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
23	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	3.4	28
24	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	12.6	534
25	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion, 2020, 60, 1024-1031.	1.6	32
26	Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1. Proceedings (mdpi), 2020, 50, .	0.2	0
27	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host and Microbe, 2020, 28, 486-496.e6.	11.0	178
28	Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. Cell Host and Microbe, 2020, 27, 262-276.e4.	11.0	29
29	Development of an antibody cocktail for treatment of Sudan virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3768-3778.	7.1	23
30	Convalescent plasma antiâ€“SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. Journal of Clinical Investigation, 2020, 130, 6728-6738.	8.2	172
31	Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors. EBioMedicine, 2019, 46, 215-226.	6.1	2
32	Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathogens, 2019, 15, e1008061.	4.7	35
33	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	2.1	70
34	Synthesis and Structureâ€“Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-<i>b</i>]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity. Journal of Medicinal Chemistry, 2019, 62, 5810-5831.	6.4	44
35	Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion. Viruses, 2019, 11, 410.	3.3	27
36	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	2.1	224

#	Article	IF	Citations
37	Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nature Structural and Molecular Biology, 2019, 26, 204-212.	8.2	30
38	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host and Microbe, 2019, 25, 39-48.e5.	11.0	83
39	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host and Microbe, 2019, 25, 49-58.e5.	11.0	82
40	Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nature Communications, 2019, 10, 105.	12.8	45
41	Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Journal of Biological Chemistry, 2018, 293, 6201-6211.	3.4	7
42	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	2.1	153
43	A Serological Point-of-Care Test for the Detection of IgG Antibodies against Ebola Virus in Human Survivors. ACS Nano, 2018, 12, 63-73.	14.6	163
44	Protocadherin-1 is essential for cell entry by New World hantaviruses. Nature, 2018, 563, 559-563.	27.8	84
45	Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles. Journal of Infectious Diseases, 2018, 218, S365-S387.	4.0	40
46	Enhancement of Ebola virus infection by seminal amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7410-7415.	7.1	21
47	Optimization of Isothiazolo[4,3-<i>b</i>]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity. Journal of Medicinal Chemistry, 2018, 61, 6178-6192.	6.4	36
48	The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells. Frontiers in Immunology, 2018, 9, 1428.	4.8	22
49	Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. Viruses, 2018, 10, 286.	3.3	16
50	Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. Journal of Infectious Diseases, 2018, 218, S636-S648.	4.0	19
51	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	11.0	182
52	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173
53	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	2.1	173
54	Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Science Translational Medicine, 2017, 9, .	12.4	23

#	Article	IF	Citations
55	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017, 19, 413-424.	6.4	66
56	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. Journal of Virology, 2017, 91, .	3.4	23
57	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	28.9	145
58	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	28.9	103
59	Convalescent Plasma and the Dose of Ebola Virus Antibodies. New England Journal of Medicine, 2017, 376, 1296-1297.	27.0	6
60	Generation and characterization of protective antibodies to Marburg virus. MAbs, 2017, 9, 696-703.	5.2	28
61	Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Immunology Letters, 2017, 190, 289-295.	2.5	2
62	Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. Journal of Experimental Medicine, 2017, 214, 2563-2572.	8.5	15
63	Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. Nature Microbiology, 2017, 2, 17113.	13.3	104
64	Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcÎ³RI. Scientific Reports, 2017, 7, 6054.	3.3	13
65	NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host and Microbe, 2017, 22, 688-696.e5.	11.0	108
66	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	3.3	22
67	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	27.8	3
68	Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses, 2016, 8, 94.	3.3	18
69	Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. Viruses, 2016, 8, 133.	3.3	8
70	A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. MSphere, 2016, 1, .	2.9	25
71	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	2.1	407
72	A â€œTrojan horseâ€•bispecific-antibody strategy for broad protection against ebolaviruses. Science, 2016, 354, 350-354.	12.6	101

#	Article	IF	Citations
73	Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Vaccine Journal, 2016, 23, 717-724.	3.1	40
74	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Scientific Reports, 2016, 6, 24897.	3.3	35
75	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	5.6	17
76	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Scientific Reports, 2016, 6, 19193.	3.3	27
77	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	6.4	80
78	Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. ACS Infectious Diseases, 2016, 2, 173-179.	3.8	33
79	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Journal of Virology, 2016, 90, 266-278.	3.4	92
80	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Journal of Virology, 2016, 90, 279-291.	3.4	72
81	Interferon Î±/Î² Receptorâ€"Deficient Mice as a Model for Ebola Virus Disease. Journal of Infectious Diseases, 2015, 212, S282-S294.	4.0	56
82	Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio, 2015, 6, e00801.	4.1	100
83	Immune Memory to Sudan Virus: Comparison between Two Separate Disease Outbreaks. Viruses, 2015, 7, 37-51.	3.3	20
84	Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis <i>In Vivo</i>. MBio, 2015, 6, e00565-15.	4.1	65
85	Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases, 2015, 212, S425-S434.	4.0	49
86	Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. PLoS ONE, 2015, 10, e0118881.	2.5	50
87	Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. PLoS ONE, 2015, 10, e0137786.	2.5	24
88	Calcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic Intervention. PLoS Pathogens, 2015, 11, e1005220.	4.7	42
89	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. ELife, 2015, 4, .	6.0	110
90	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of Virology, 2014, 159, 1229-37.	2.1	59

#	Article	IF	Citations
91	Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation. PLoS ONE, 2014, 9, e89735.	2.5	43
92	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	3.3	49
93	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. Viruses, 2014, 6, 4666-4682.	3.3	22
94	Discussions and decisions of the 2012â€"2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012â€"June 2013. Archives of Virology, 2014, 159, 821-830.	2.1	85
95	Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge. ACS Chemical Biology, 2014, 9, 2263-2273.	3.4	23
96	Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemannâ€"Pick C1. Virology, 2014, 468-470, 637-646.	2.4	55
97	Lassa virus entry requires a trigger-induced receptor switch. Science, 2014, 344, 1506-1510.	12.6	251
98	Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 1425-1432.	2.1	54
99	Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 301-311.	2.1	99
100	Persistent Immune Responses after Ebola Virus Infection. New England Journal of Medicine, 2013, 369, 492-493.	27.0	44
101	Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus. Journal of Virology, 2013, 87, 4952-4964.	3.4	87
102	Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu). Journal of Infectious Diseases, 2013, 208, 299-309.	4.0	47
103	Structural Basis for Differential Neutralization of Ebolaviruses. Viruses, 2012, 4, 447-470.	3.3	63
104	Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay. Vaccine Journal, 2012, 19, 1844-1852.	3.1	26
105	Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO Journal, 2012, 31, 1947-1960.	7.8	284
106	Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5034-5039.	7.1	246
107	Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection. PLoS ONE, 2012, 7, e50316.	2.5	44
108	Ebola virus entry requires the cholesterol transporter Niemannâ€"Pick C1. Nature, 2011, 477, 340-343.	27.8	1,127

#	Article	IF	Citations
109	A shared structural solution for neutralizing ebolaviruses. Nature Structural and Molecular Biology, 2011, 18, 1424-1427.	8.2	113
110	Filovirius vaccines. Hum Vaccin, 2011, 7, 701-711.	2.4	29
111	Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector. Vaccine Journal, 2010, 17, 572-581.	3.1	94